全文获取类型
收费全文 | 247391篇 |
免费 | 18412篇 |
国内免费 | 1117篇 |
专业分类
耳鼻咽喉 | 2780篇 |
儿科学 | 6460篇 |
妇产科学 | 4608篇 |
基础医学 | 32217篇 |
口腔科学 | 4535篇 |
临床医学 | 24993篇 |
内科学 | 52207篇 |
皮肤病学 | 3387篇 |
神经病学 | 23865篇 |
特种医学 | 8359篇 |
外国民族医学 | 11篇 |
外科学 | 38414篇 |
综合类 | 3423篇 |
一般理论 | 318篇 |
预防医学 | 20879篇 |
眼科学 | 6501篇 |
药学 | 16884篇 |
4篇 | |
中国医学 | 357篇 |
肿瘤学 | 16718篇 |
出版年
2023年 | 1211篇 |
2022年 | 933篇 |
2021年 | 4798篇 |
2020年 | 3263篇 |
2019年 | 5304篇 |
2018年 | 5954篇 |
2017年 | 4476篇 |
2016年 | 4959篇 |
2015年 | 5831篇 |
2014年 | 8615篇 |
2013年 | 11807篇 |
2012年 | 18026篇 |
2011年 | 18912篇 |
2010年 | 10582篇 |
2009年 | 9443篇 |
2008年 | 16617篇 |
2007年 | 17465篇 |
2006年 | 17327篇 |
2005年 | 17289篇 |
2004年 | 16184篇 |
2003年 | 15032篇 |
2002年 | 14033篇 |
2001年 | 2082篇 |
2000年 | 1566篇 |
1999年 | 2151篇 |
1998年 | 2573篇 |
1997年 | 2089篇 |
1996年 | 1785篇 |
1995年 | 2046篇 |
1994年 | 1702篇 |
1993年 | 1531篇 |
1992年 | 1243篇 |
1991年 | 1169篇 |
1990年 | 1006篇 |
1989年 | 984篇 |
1988年 | 957篇 |
1987年 | 963篇 |
1986年 | 939篇 |
1985年 | 984篇 |
1984年 | 1205篇 |
1983年 | 1119篇 |
1982年 | 1323篇 |
1981年 | 1285篇 |
1980年 | 1122篇 |
1979年 | 696篇 |
1978年 | 736篇 |
1977年 | 621篇 |
1976年 | 575篇 |
1975年 | 465篇 |
1974年 | 478篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Robinson Sandra M. Scott Jason Ryan Sarah Adams Nicola Hassell Andrew Walker David 《Clinical rheumatology》2022,41(12):3869-3877
Clinical Rheumatology - Educating patients about methotrexate is a core role of rheumatology nurses. We have previously reported the scoring of videoed interviews of rheumatology nurses educating... 相似文献
5.
Dambach Micha Fieber Jakob Wanzenried Manuel Fehr Tobias Konrad Christoph Goertz Roland Fieber David 《Der Anaesthesist》2022,71(11):846-851
Die Anaesthesiologie - Die Anwendung von hohen Sauerstoffkonzentration birgt Gefahren für Patienten und Anwender. Hohe Umgebungskonzentrationen an Sauerstoff bergen die Gefahr von... 相似文献
6.
7.
8.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.
Jacey Nishiguchi Anusha McNamara Colleen S. Surlyn Kellene Vokaty Eagen Laura Feeney Vivian Lian David E. Smith 《Journal of viral hepatitis》2022,29(1):21-25
In 2016, an eConsult service was developed within a safety net health system to expand access to hepatitis C (HCV) treatment in the primary care setting. The eConsult system provides individualized treatment recommendations from specially trained primary care pharmacists and primary care physicians to primary care providers with less experience in the rapidly changing treatment of HCV. Since its launch, this service has had a large impact in expanding care to a largely homeless and low-income urban population within our health system. We now aim to evaluate its efficacy in curing HCV. In this retrospective cohort study, we describe rates of sustained virologic response 12 weeks after treatment completion (SVR12) for those who received primary care-based HCV treatment through the eConsult system with those who were treated in primary care independent of an eConsult from 2017 to 2019. We found there was no significant difference in the proportion of patients who achieved SVR12 between the two groups. Overall, >90% of patients who received treatment achieved SVR12. Approximately 40% of patients treated for HCV received an eConsult, suggesting utility of the eConsult in expanding access and coordinating treatment for patients within our network. 相似文献